08 Dec 2023  |  North America
Public Funding and Large Biopharma Investments Support Technological Advancements and Improved Analysis
In recent years, single-cell analysis has changed rapidly. It began as a niche, specialized technology with few companies offering solutions, which then became commonly used in academia. Subsequently, its use has spread to areas such as biopharma, with more companies investing in the research and development (R&D) of single-cell analysis projects. ...
22 Sep 2022  |  North America
Integration of Clinical Genomics and AI will lead to definitive Transformational Growth in the Next Decade
Clinical genomics regained significance during the pandemic with the development of the mRNA COVID-19 vaccine, and several non-invasive at-home test kits; an unprecedented feat in recent times. Genomics will take center stage, as large genome sequencing and research will continuously create data for new therapeutics. Artificial Intelligence (AI) an...
30 Nov 2020  |  Europe
Investment in Genomics, Advanced Therapies, and Precision Health Offers New Opportunities for the UK MedTech Market
Innovation Culture in the Life Sciences Sector Enables Growth Despite the Short-term Impact of COVID-19 and Brexit
The United Kingdom (UK) medical technology (MedTech) market is experiencing a transformational phase. Although it achieved steady growth up to 2019 and was infused with investments as part of the UK Life Sciences Sector Deal, market and regulatory challenges persist. In this research study, Frost & Sullivan analyzes the UK MedTech market landscape ...
03 Sep 2019  |  North America
Clinical Applications for Single Cell Analysis Remain a Heavily Uncontested Market Place
Single cell genomic and proteomics tools have gained significant importance in the past 2 years. The year 2018 was particularly very active with a lot of platforms made available by both established life sciences tools companies and start-ups. 10X Genomics and Fluidigm have demonstrated the potential for high-throughput single cell applications. Th...
31 Mar 2014  |  Global
The future of healthcare is moving towards become more personalized. An individuals genetic information is become a crucial component to assess the risks and predispositions one has towards acquiring a while host of indications. Embracing genetic best tests, will help world economies by reducing the millions of dollars spent in present diagnostic a...
23 Nov 2009  |  North America
This issue of Vital Signs, released on November 23, 2009, provides a strategic overview of trends in pharmacogenomic testing and drug development. Additionally, a company spotlight is provided for Paratek Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of innovative new therapies that treat and prevent ...
04 Feb 2008  |  North America
This issue of Vital Signs, released on February 4, 2008, provides an strategic overview of the integration of genomics technology in proteomics analysis. Additionally, a company spotlight is provided for MSM Protein Technologies, an emerging biotechnology company with a suite of tools for drug discovery of functional antibodies and proteins against...
27 Aug 2007  |  North America
Vital Signs - Bringing Life Sciences Technologies Directly to the Consumer: How Genomics is Getting More Personal
This issue of Vital Signs, released on August 27, 2007, provides a strategic overview of emerging market opportunities for life sciences companies as they relate to direct-to-consumer genetic testing and personal genomics. Additionally, a company spotlight is provided for SeqWright DNA Technology Services, a provider of custom DNA sequencing and re...
30 Jun 2007  |  Global
This research service outlines the key developments in the field of functional genomics.
20 Dec 2006  |  North America
This research service provides a strategic analysis of genomics markets within the United States. The market was divided into the total U.S. nucleic acid isolation markets, total U.S. PCR markets, total U.S. qRT-PCR markets, total U.S. DNA microarray markets, and total U.S. DNA sequencing technology markets. Each segment covers market trends, tech...
16 Oct 2006  |  Europe
This strategic analysis service provides a detailed analysis of the European pharmacogenomics market. An indepth analysis of marketing parameters (revenues, forecasts, geographic trends and market share) coupled with competitive factors and strategies for sustained market prevalence are reported.
31 Dec 2005  |  Global
This research service analyzes emerging technologies in the field of pharmacogenomics and their impact on the healthcare industry
27 Jun 2005  |  Asia Pacific
The report covers the major attributes of Genomics and Proteomics Markets in Australia. The Executive summary gives the details of teh report in brief. A separate analysis of the Genomics and Proteomics markets have been done giving details about the market size from the year 2002-2007. Apart from this, a total market analysis was done along with c...
31 Dec 2004  |  Europe
This research service tracks, analyzes and profiles emerging technologies, especially genomics and proteomics for drug discovery in Europe
04 Oct 2002  |  North America
Only 2 to 3 percent of the Human Genome sequence contains regulatory information. Knowing how genes are regulated can open a wide field of commercial opportunities, some of which are being persued under the umbrella term of functional genomics. This field spans mutational (wetlab) and expression analysis (microarray) technologies, and is tied toge...
06 Jun 2001  |  North America
The U.S. Pharmacogenomics Market report focuses on the varying dynamics of the pharmacogenomics market. This report covers the Pharmacogenomics services, Gene-based Diagnostics, and Orphan Drugs segments. This report provides an in-depth analysis of the revenue sales forecasts for the market, drivers and restraints that affect the current and futu...
16 Aug 1999  |  Global
05 Nov 1998  |  Global
13 Apr 1998  |  Global